^
Association details:
| Biomarker: | CD34 underexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
THE PROGNOSTIC ROLE OF CD34 ANGIOGENESIS MARKER IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
Published date:
06/12/2020
Excerpt:
Overall response on RCHOP immunotherapy was in 42 (87.5%) patients with low-level CD34 expression...CD34 expression status on microenvironment cells can be an important prognostic factor in therapy response achievement and overall survival in patients with DLBCL.
